The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a) by Helmbold, Alan F. et al.
Hindawi Publishing Corporation
Cholesterol
Volume 2010, Article ID 306147, 3 pages
doi:10.1155/2010/306147
Clinical Study
The Effectsof Extended Release Niacin in
Combination with Omega3 Fatty Acid Supplements in
the Treatmentof Elevated Lipoprotein (a)
AlanF.Helmbold, JenniferN.Slim,Jennifer Morgan,LaudinoM.Castillo-Rojas,
EricA.Shry,andAhmad M.Slim
Brooke Army Medical Center, MCHE MDC Cardiology Service, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200, USA
Correspondence should be addressed to Ahmad M. Slim, ahmad.slim@us.army.mil
Received 28 September 2009; Revised 18 December 2009; Accepted 22 December 2009
Academic Editor: Gerhard M. Kostner
Copyright © 2010 Alan F. Helmbold et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objective. To assess the eﬀectiveness of niacin/ﬁsh oil combination therapy in reducing Lipoprotein (a) [Lp(a)] levels after twelve
weeks of therapy. Background.Lipoprotein(a)accumulates inatherosclerotic lesionsandpromotessmoothmuscle cellgrowthand
is both atherogenic and thrombogenic. A clinical trials of combination therapy for the reduction of Lp(a) has not been previously
reported. Methods. The study was an observational study following subjects with an elevated Lp(a) (>70nmol/L) to assess impact
of 12 weeks of combination Omega 3FA, niacin, and the Mediterranean diet on Lp(a). Results. Twenty three patients were enrolled
with 7 patients lost to follow up and 2 patients stopped due to adverse events. The average Lp(a) reduction in the remaining 14
subjects after 12 weeks of combination therapy was 23% ± 17%[P = .003] with a signiﬁcant association of the reduction of Lp(a)
with increasing baseline levels of Lp(a) [R
2 = 0.633, P = .001]. Conclusions. There was a signiﬁcant reduction in Lp(a) levels with
combination therapy. A more pronounced eﬀect was noted in patients with higher baseline levels of Lp(a).
1. Background/Review of the Literature
AccordingtotheFraminghamstudy,alipoprotein(a)[Lp(a)]
>30mg/dL or >75nmol/L (assay dependent) is an inde-
pendent risk factor (RF) correlating to a two- to three-fold
increased risk for CAD [1, 2]. When associated with other
lipid abnormalities, this risk increases 6–9 times normally
[3]. Further, patients with established CAD who have
elevated Lp(a) levels are more likely to have acute coronary
syndrome (ACS) and in those patients with ACS, baseline
Lp(a) levels are predictive of sudden cardiac death [4, 5].
The Lp(a) particle has also been shown to be both
atherogenic and thrombogenic. Thrombogenicity is partially
due to kringle 4 repeats homology to plasminogen thus
impairing thrombolysis by competitive inhibition [6, 7].
The literature has illustrated reduction of Lp(a) levels via
high-dose niacin [8, 9], omega 3FA supplements [10–12],
fenoﬁbrate [13], hormone therapy/estrogen replacement
therapy [14], tamoxifen therapy [14], aspirin therapy [15],
and combination of ascorbic acid 3 grams and lysine 3 grams
(Linus Pauling Therapy) [16]a sw e l la sL - c a r n i t i n e[ 17]. The
Lp(a)attachmentpreventsLDLparticlefrombindingtoLDL
receptors in the liver and thus statin therapy is ineﬀective
at lowering Lp(a) values [18–20]. There are no prior case
series or trials of combination therapy for lowering Lp(a)
values; however, a case report from our institution did note a
70% reduction in Lp(a) levels with combination niacin-ER,
omega 3FA supplements, and dietary modiﬁcation [21].
2.Research DesignandMethods
This was an observational longitudinal study following
subjects documented to have an elevated Lp(a) (>75nmol/L
with ELISA method in our institution) to assess impact
of 12 weeks of combination of ﬁsh oil, niacin, and the
Mediterranean diet on Lp(a). Subjects served as their own
controls.TheappropriatetestisarepeatedmeasuresANOVA2 Cholesterol
followed by paired t-tests corrected for multiple compar-
isons. A sample size of 9 subjects was estimated to detect
a 70nmol/L reduction (with a power of 80% and a level
of conﬁdence of 95%). We proposed recruiting 20 subjects
to allow for possible drop out of 50% in austere military
environment. Subjects were candidates for the study if they
were 18 years of age or older with an Lp(a) > 75nmol/L.
Subjects were excluded if they were pregnant, lactating,
diabetic, had a history of gout, recent myocardial infarction
(less than 6 weeks), history of liver disease or abnormal liver
transaminases (>3x ULN), and could not have taken either
omega 3FA supplements or a niacin product during the 3
months proceeding enrollment into the study.
Patients were initially started on extended release niacin
(Niaspan) at 500mg daily and titrated up by increment of
500mg per week until the target dose of 2gm was reached.
Patients were instructed to eat a small low fat snack and to
take enteric coated aspirin 325mg 30–45 minutes prior to
taking niacin to assist with minimizing hot ﬂash symptoms.
After titrating niaspan to 2gm daily, subjects were provided
with reading materials related to the Mediterranean diet
and encouraged to implement the Mediterranean style of
eating as much as possible. Patients were also started on
omega 3FA supplements one tab by mouth, three times a
day. The ﬁsh oil capsules contained 600mg of EPA and
240mg of DHA per capsule. After 12 weeks of therapy with
2gm of extended-release niacin, omega 3FA supplements,
and implementation of the Mediterranean diet, ﬁnal serum
concentrations of Lp(a) were obtained. There were no blood
draws performed prior to the 12 weeks mark to assess the
eﬀect of individual agent on Lp(a). This study does not take
into account individual drug eﬀect, but rather the synergistic
eﬀect of all the 3 drugs combined. The primary endpoint of
the study was the percent change in Lp(a) after 12 weeks of
therapy compared to baseline.
3. Results
Twenty three subjects were enrolled initially with 7 patients
lost to follow up due to deployment and 2 patients stopped
due to adverse events. One subject dropped due to severe
hot ﬂashes and the other subject due to elevated hepatic
transaminases unrelated to the study drug. The total number
of subjects who completed the study was 14. The average
Lp(a) reduction after 12 weeks of combination therapy
was 23%± 17% which was statistically signiﬁcant with a
P = .003 (see Figure 1). The majority of the reduction was
noted in subjects with baseline Lp(a) more than 200nmol/L
which was also statistically signiﬁcant with a P = .001
(see Figure 2). However, the study was not powered to
draw conclusions based on subgroup analysis and was
merely a pilot observational study aimed at assessing percent
reduction with niacin/Fish oil combination therapy.
4. Discussion
This study serves as a ﬁrst step in evaluating the eﬃcacy
of combination niacin/ﬁsh oil therapy on reducing Lp(a)
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Figure 1:ThepercentreductioninLp(a)asobservedafter12weeks
of niacin/ﬁsh oil combination therapy.
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Figure 2: The more pronounced trend in percent reduction in
Lp(a) as observed after 12 weeks of niacin/ﬁsh oil combination
therapy in patients with baseline Lp(a) > 200nmol/L.
values. We demonstrated a signiﬁcant reduction of Lp(a)
using a combination regimen of extended-release niacin,
omega-3FA, and the Mediterranean diet. Based on our pilot
study, there may be linear relationship between the baseline
level of Lp(a) and the beneﬁt observed in combination
therapy, with baseline Lp(a) levels more than 200nmol/L
deriving the greatest beneﬁt. There are obvious limitations
to the study design including small sample size, a signiﬁcant
dropout rate (most due to military deployment during
wartime) and short duration of therapy, absence of blood
draws prior to the 12 weeks mark to assess the eﬀect of
individual agent on Lp(a), as well as not being able to
account for individual drug eﬀect on Lp(a). Further, there
are some patients who are unable to tolerate this therapy,Cholesterol 3
as evidenced by two patient’s withdrawal from the study.
Despite these limitations, the study provided us with an
insight into the eﬀectiveness of niacin ﬁsh oil therapy in
treating Lp(a) beyond anecdotal data. It also generates a
possible hypothesis that patients with higher baselines Lp(a)
(>200nmol/L) might beneﬁt the most from such therapy.
However, such conclusion could be skewed by the marked
reduction observed in one subject with baseline Lp(a)
exceeding 500nmol/L and larger studies might be needed
to assess if such observed response is clinically signiﬁcant
or just a statistical anomaly. Furthermore, it remains to be
investigated if such reduction in Lp(a) with combination
therapy translates into reduction in observed cardiovascular
outcomes.
5. Conclusions
Our pilot study demonstrates that a statistically signiﬁcant
reduction in Lp(a) levels can be achieved with combination
therapy. This serves as the basis for future larger prospective,
randomizedstudiestospeciﬁcallyaddressthereproducibility
of our data and the correlation of such reduction with
cardiovascular outcome.
Acknowledgments
Twin Labs (maker of the ﬁsh oil capsule used in the
study) provided the ﬁsh oil capsules needed as a gift in
kind. Similarly, Kos Pharmaceuticals (maker of niacin-ER)
provided the niacin-ER needed for the study and a $4,500.00
grant.
References
[1] A. G. Bostom, L. A. Cupples, J. L. Jenner, et al., “Elevated
plasma lipoprotein(a) and coronary heart disease in an aged
55 years and younger a prospective study,” The Journal of the
American Medical Association, vol. 276, pp. 544–548, 1996.
[2] S. M. Marcovina, et al., “The eﬀe c to fm e t h o d o l o g i c a l
diﬀerences in the measurement of Lp(a) on the interpretation
of clinical data,” International Congress Series, vol. 1262, pp.
558–561, 2004.
[3] H. R. Superko and H. S. Hecht, “Metabolic disorders con-
tribute to subclinical coronary atherosclerosis in patients with
coronary calciﬁcation,” American Journal of Cardiology, vol.
88, no. 3, pp. 260–264, 2001.
[4] G.Dangas,R.Mehran,P.C.Harpel,etal.,“Lipoprotein(a)and
inﬂammation in human coronary atheroma: association with
the severity of clinical presentation,” Journal of the American
College of Cardiology, vol. 32, no. 7, pp. 2035–2042, 1998.
[5] P. J. Stubbs, M. Seed, D. Lane, P. Collinson, F. Kendall, and M.
Noble,“Lipoprotein(a)asariskpredictorforcardiacmortality
in patients with acute coronary syndromes,” European Heart
Journal, vol. 19, no. 9, pp. 1355–1364, 1998.
[6] L. A. Miles, G. M. Fless, E. G. Levin, A. M. Scanu, and E. F.
Plow, “A potential basis for the thrombotic risks associated
with lipoprotein(a),” Nature, vol. 339, no. 6222, pp. 301–303,
1989.
[ 7 ]D .I .S i m o n ,G .M .F l e s s ,A .M .S c a n u ,a n dJ .L o s c a l z o ,
“Tissue type plasminogen activator binds to and is inhibited
bysurface-boundlipoprotein(a)andlow-densitylipoprotein,”
Biochemistry, vol. 30, pp. 6671–6677, 1991.
[8] J. Pan, M. Lin, R. L. Kesala, J. Van, and M. A. Charles,
“Niacin treatment of the atherogenic lipid proﬁle and Lp(a)
in diabetes,” Diabetes, Obesity and Metabolism,v o l .4 ,n o .4 ,
pp. 255–261, 2002.
[9] S. M. Grundy, G. L. Vega, M. E. McGovern, et al., “Eﬃcacy,
safety, and tolerability of once-daily niacin for the treatment
of dyslipidemia associated with type 2 diabetes: results of the
assessmentofdiabetescontrolandevaluationoftheeﬃcacy of
Niaspan trial,” Archives of Internal Medicine, vol. 162, no. 14,
pp. 1568–1576, 2002.
[10] W. Herrmann, J. Biermann, and G. M. Kostner, “Comparison
of eﬀects of N-3 to N-6 fatty acids on serum level of lipopro-
tein(a) in patients with coronary artery disease,” American
Journal of Cardiology, vol. 76, no. 7, pp. 459–462, 1995.
[11] F. U. Beil, W. Terres, M. Orgass, and H. Greten, “Dietary ﬁsh
oil lowers lipoprotein(a) in primary hypertriglyceridemia,”
Atherosclerosis, vol. 90, no. 1, pp. 95–97, 1991.
[12] O. Haglund, J. L. Mehta, and T. Saldeen, “Eﬀects of ﬁsh oil on
some parameters of ﬁbrinolysis and lipoprotein(a) in healthy
subjects,” American Journal of Cardiology, vol. 74, no. 2, pp.
189–192, 1994.
[13] M. Farnier, F. Bonnefous, N. Debbas, and A. Irvine, “Compar-
ative eﬃcacy and safety of micronized fenoﬁbrate and simvas-
tatin in patients with primary type IIa or IIb hyperlipidemia,”
Archives of Internal Medicine, vol. 154, no. 4, pp. 441–449,
1994.
[14] K. M. Dalessandri, “Multiple methods for reduction of
lipoprotein(a),” Atherosclerosis, vol. 163, no. 2, pp. 409–410,
2002.
[15] M. Akaiek, H. Azuma, A. Kagawa, et al., “Eﬀect of aspirin
treatment on serum concentrations of lipoprotein(a) in
patients with atherosclerotic diseases,” Clinical Chemistry, vol.
48, no. 9, pp. 1454–1459, 2002.
[16] K. M. Dalessandri, “Reduction of lipoprotein(a) in post-
menopausal women,” Archives of Internal Medicine, vol. 161,
no. 5, pp. 772–773, 2001.
[17] G. Derosa, A. F. Cicero, A. Gaddi, A. Mugellini, L. Ciccarelli,
and R. Fogari, “The eﬀect of L-carnitine on plasma lipopro-
tein(a) levels in hypercholesterolemic patients with type 2
diabetes mellitus,” Clinical Therapeutics,v o l .2 5 ,n o .5 ,p p .
1429–1439, 2003.
[18] A. L. White and R. E. Lanford, “Biosynthesis and metabolism
of lipoprotein(a),” Current Opinion in Lipidology, vol. 6, pp.
75–80, 1995.
[19] S. M. Marcovina and J. D. Morrisett, “Structure and
metabolism of lipoprotein(a),” Current Opinion in Lipidology,
vol. 6, pp. 136–145, 1995.
[ 2 0 ]J .T h i e r y ,V .W .A r m s t r o n g ,J .S c h l e e f ,C .C r e u t z f e l d t ,W .
Creutzfeldt, and D. Seidel, “Serum lipoprotein Lp(a) con-
centrations are not inﬂuenced by an HMG CoA reductase
inhibitor,” Klinische Wochenschrift, vol. 66, no. 10, pp. 462–
463, 1988.
[21] A. F. Helmbold, “Management of elevated lipoprotein(a)
via initial dietary modiﬁcation and omega 3 fatty acid
supplements: a case report,” in Proceedings of the International
Symposium on Triglycerides, Metabolic Disorders, and Cardio-
vascular Disease, New York, NY, USA, July 2003.